CIK 0001420720
- Non-accelerated filer
- Smaller reporting company
iBio, Inc.
Sign in to watch- Ticker
- IBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 262797813
- Phone
- +1 302-355-0650
- Business address
- 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY, 10022-1737
- Former names
- iBio, Inc., iBioPharma, Inc., InB:Biotechnologies, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-08-07 | Eastern Capital LTD 10% owner | Sale | −1,355,604 | $3.83 | $5.2M | 31,758,993 |
| 2020-08-07 | Eastern Capital LTD 10% owner | Conversion · Series B Preferred Stock | −5,785 | 0 | ||
| 2020-08-06 | Eastern Capital LTD 10% owner | Sale | −2,768,137 | $4.18 | $11.6M | 33,114,597 |
| 2020-08-05 | Eastern Capital LTD 10% owner | Sale | −900,000 | $4.46 | $4.0M | 35,882,734 |
| 2020-08-04 | Eastern Capital LTD 10% owner | Sale | −600,000 | $4.39 | $2.6M | 36,782,734 |
| 2020-06-12 | Kay Robert Director | Grant or award · Stock Option | +400,000 | 400,000 | ||
| 2020-06-12 | Kay Robert Director | Grant or award · Stock Option | +400,000 | 400,000 | ||
| 2020-06-04 | ERWIN ROBERT L President | Option exercise | +28,268 | $0.93 | $26K | 108,108 |
| 2020-06-04 | ERWIN ROBERT L President | Sale | −28,268 | $1.71 | $48K | 108,108 |
| 2020-06-04 | ERWIN ROBERT L President | Option exercise · Stock Option (right to buy) | −28,268 | 108,108 | ||
| 2020-06-02 | ERWIN ROBERT L President | Option exercise | +96,124 | $0.93 | $89K | 136,376 |
| 2020-06-02 | ERWIN ROBERT L President | Sale | −96,124 | $1.62 | $156K | 136,376 |
| 2020-06-02 | ERWIN ROBERT L President | Option exercise · Stock Option (right to buy) | −96,124 | 136,376 | ||
| 2020-05-27 | Mullaney James P. Chief Financial Officer | Option exercise | +11,250 | $0.93 | $10K | 0 |
| 2020-05-27 | Mullaney James P. Chief Financial Officer | Sale | −11,250 | $1.61 | $18K | 0 |
| 2020-05-27 | Mullaney James P. Chief Financial Officer | Option exercise · Stock Option (right to buy) | −11,250 | 0 | ||
| 2020-04-21 | Isett Thomas Francis 3rd CEO and Executive Chairman | Grant or award · Stock Option (right to buy) | +975,000 | $0.90 | $873K | 1,275,000 |
| 2020-03-19 | Isett Thomas Francis 3rd CEO and Executive Co-Chairman | Conversion | +100,000 | $0.20 | $20K | 1,275,000 |
| 2020-03-19 | Isett Thomas Francis 3rd CEO and Executive Co-Chairman | Conversion · Series C Convertible Preferred Stock | +20 | $1,000.00 | $20K | 1,275,000 |
| 2020-03-17 | Isett Thomas Francis 3rd CEO and Executive Co-Chairman | Option exercise | +78,024 | $0.22 | $17K | 1,275,000 |
Page 6 of 7 · 126 trades